Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb raised 2026 revenue guidance to $49.0B-$50.0B after Q2 revenue rose 6% to $13.0B and Growth Portfolio sales increased 15% to $7.6B, while Novo Nordisk expects 2026 constant-currency sales to range from flat to down 6%. BMY has outperformed, gaining more than 35% over the past year versus a more than 30% decline for NVO, and trades more cheaply at 9.1x forward P/E versus 12.6x. The article favors BMY on improving growth and valuation, though Medicare pricing, generic competition, litigation and higher leverage remain material risks.

Analysis

The key investable distinction is not headline growth versus decline, but durability of incremental earnings. BMY’s portfolio transition can support a multiple re-rating only if new-product gross profit offsets the accelerating price/generic erosion embedded in legacy franchises; a low P/E is partly compensation for this execution burden and for legal overhangs. The upcoming earnings print is therefore a quality-of-growth test: sustained Growth Portfolio expansion with stable operating margin would justify a 1-2x forward P/E closing versus large-cap pharma peers over the next 3-6 months.

NVO’s de-rating is vulnerable to becoming self-reinforcing: lower volume/price expectations reduce manufacturing absorption, while payer pressure and competitive formulary access can force further concessions. LLY is the clearest second-order beneficiary, since any NVO execution or access shortfall shifts prescriber and payer leverage toward tirzepatide rather than shrinking the obesity market. Conversely, NVO’s balance-sheet capacity gives it room to defend share through pricing and direct cash-pay channels, making an outright short risky after a large decline.

The contrarian view is that BMY’s apparent free-cash-flow advantage may be less informative than its sustainability: mature-drug cash flows face a structurally higher decay rate, while NVO retains a large installed base and substantial operating leverage if obesity demand stabilizes. Thus, the cleaner expression is relative, not directional. Over 6-18 months, Medicare pricing implementation and obesity competition favor lower sector multiples broadly, but differentiated pipeline readouts can dominate valuation screens.

Key Decisions for Investors

• Initiate a 3-6 month long BMY / short NVO dollar-neutral pair ahead of BMY earnings, sized modestly. Target 10-15% relative outperformance; exit if BMY Growth Portfolio growth decelerates materially or management lowers revenue/operating-margin guidance.
• Prefer LLY over NVO for obesity exposure over the next 6-12 months: maintain/add LLY on broad GLP-1 weakness rather than shorting NVO outright. The thesis fails if NVO demonstrates sustained share gains without incremental price concessions or if LLY supply constraints re-emerge.
• Do not add outright BMY exposure solely on the valuation discount. Require confirmation that growth products are offsetting legacy erosion in both revenue and gross-margin dollars; adverse litigation developments or a meaningful guidance cut would likely eliminate the rerating case.
• Monitor U.S. net-price trends, formulary changes, and quarterly prescription/volume data for both NVO and LLY. A stabilization in NVO sales expectations is the near-term catalyst to cover the NVO leg, potentially producing a sharp short-covering rally after the prior sentiment reset.